{"publisher":"Semaglutide Labs","product":"Semaglutide","preparedAt":"2026-11-07","reviewStatus":"Research drafts; medical review has not been claimed","facts":[{"label":"Research finding 1","text":"STEP1 randomized 1961 adults without diabetes to subcutaneous 2.4 mg semaglutide or placebo plus lifestyle support for 68 weeks.","href":"https://pubmed.ncbi.nlm.nih.gov/33567185/"},{"label":"Research finding 2","text":"Mean weight change in STEP1 was−14.9% versus−2.4% with placebo; gastrointestinal events caused discontinuation in 4.5% versus 0.8%.","href":"https://pubmed.ncbi.nlm.nih.gov/33567185/"},{"label":"Research finding 3","text":"SELECT enrolled 17604 adults aged 45 or older with established cardiovascular disease and overweight/obesity but no diabetes.","href":"https://pubmed.ncbi.nlm.nih.gov/37952131/"},{"label":"Research finding 4","text":"SELECT major cardiovascular events occurred in 6.5% with semaglutide versus 8.0% with placebo; hazard ratio 0.80 over mean 39.8 months follow-up.","href":"https://pubmed.ncbi.nlm.nih.gov/37952131/"}],"sources":[{"title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity.","href":"https://pubmed.ncbi.nlm.nih.gov/33567185/"},{"title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.","href":"https://pubmed.ncbi.nlm.nih.gov/37952131/"},{"title":"WEGOVY (semaglutide) injection and tablets: full prescribing information, revised June2026","href":"https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b"},{"title":"FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss","href":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"}],"guides":[{"title":"Approved semaglutide and compounded preparations: compare the actual medicine","url":"https://semaglutidelabs.com/research-guides/approved-versus-compounded-semaglutide","description":"A practical document checklist for identifying what a semaglutide program supplies and how its evidence differs.","date":"2026-11-07"},{"title":"Semaglutide and cardiovascular outcomes: who was actually studied?","url":"https://semaglutidelabs.com/research-guides/cardiovascular-evidence-select-soul","description":"Separate SELECT and SOUL populations, outcome measures and the limits of broad heart-health claims.","date":"2026-11-07"},{"title":"Semaglutide and diabetic retinopathy: bring the eye history into the decision","url":"https://semaglutidelabs.com/research-guides/diabetic-retinopathy-history-treatment-review","description":"Understand the SUSTAIN 6 signal, later exploratory analysis and the practical need for coordinated eye-care discussion.","date":"2026-11-07"},{"title":"Semaglutide and MASH: histology, fibrosis and the approval boundary","url":"https://semaglutidelabs.com/research-guides/essence-mash-fibrosis-histology","description":"Read ESSENCE’s liver endpoints separately and match the current indication to the exact formulation and disease stage.","date":"2026-11-07"},{"title":"Semaglutide and kidney outcomes: read FLOW’s composite endpoint","url":"https://semaglutidelabs.com/research-guides/flow-kidney-outcomes-diabetes-population","description":"Understand what FLOW measured in people with type 2 diabetes and chronic kidney disease before interpreting kidney-protection claims.","date":"2026-11-07"},{"title":"Semaglutide and bone health: biomarkers are not fracture outcomes","url":"https://semaglutidelabs.com/research-guides/semaglutide-bone-density-fracture-endpoints","description":"A small randomized bone study highlights why a history of low bone density deserves a separate conversation.","date":"2026-11-07"},{"title":"Semaglutide and knee osteoarthritis: pain relief is not cartilage regeneration","url":"https://semaglutidelabs.com/research-guides/semaglutide-knee-osteoarthritis-step-nine","description":"Read STEP 9’s pain and function endpoints without expanding them into an unsupported joint-repair claim.","date":"2026-11-07"},{"title":"Wegovy, Ozempic and Rybelsus: read the product before the promise","url":"https://semaglutidelabs.com/research-guides/semaglutide-product-indication-map","description":"A route-specific map of semaglutide products, approved uses and the details to verify before comparing care.","date":"2026-11-07"},{"title":"Semaglutide salts: why the full ingredient name matters","url":"https://semaglutidelabs.com/research-guides/semaglutide-sodium-acetate-identity","description":"Understand active-ingredient identity, excipients and the limits of a certificate of analysis.","date":"2026-11-07"},{"title":"Semaglutide in HFpEF: symptoms and walking capacity are specific outcomes","url":"https://semaglutidelabs.com/research-guides/step-hfpef-symptoms-function","description":"Understand the STEP-HFpEF population and distinguish patient-reported benefit from a general heart-failure or survival claim.","date":"2026-11-07"},{"title":"What a STEP trial result can:and cannot:predict","url":"https://semaglutidelabs.com/research-guides/step-trials-weight-loss-numbers","description":"Learn to read semaglutide weight outcomes without turning an average into a personal forecast.","date":"2026-11-07"},{"title":"After semaglutide stops: what withdrawal studies actually show","url":"https://semaglutidelabs.com/research-guides/stopping-semaglutide-extension-evidence","description":"Read STEP 4 and the STEP 1 extension without turning group weight regain into a personal forecast or taper plan.","date":"2026-11-07"}]}